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Toxin Genotypes and Plasmid Profiles as Determinants of Systemic Sequelae 
in Escherichia coli 0157:H7 Infections 
Stephen M. Ostroff, Phillip I. Tarr, 
Marguerite A. Neill, Jay H. Lewis, 
Nancy Hargrett-Bean, a d John M. Kobayashi 
From the Divisions of Field Services and Bacterial Diseases, 
Center for Infectious Diseases, Centers for Disease Control, 
Atlanta, Georgia, the Divisions of Gastroenterology and 
Infectious Diseases (Departments of Pediatrics and 
Medicine), University of Washington School of Medicine, 
and the Washington State Department of Social and 
Health Services, Seattle 
In 1987, 93 Escherichia coli 0157:H7 isolates were collected uring routine surveillance 
for this pathogen in the state of Washington. Toxin genotypes and plasmid profiles were 
correlated with the clinical sequelae of illness in 88 of the 93 patients from whom these 
strains were isolated. Thirteen plasmid patterns were observed among the 88 tested iso- 
lates; four patterns accounted for 82(7o f the isolates. Genetic probing for Shiga-like 
toxins (SLT) I and II demonstrated the presence of both genes in 67 (76^0), SLT I alone 
in three (3^0), and SLT II alone in 18 (20^0). The hemolytic uremic syndrome or throm- 
botic thrombocytopenic purpura developed in seven (39^o) of 18 patients infected with 
isolates having only the SLT II gene, while these complications occurred in only four (6^0) 
of 70 patients infected with isolates having the other two genotypes (relative risk, 6.8; 
95^0 confidence interval, 1.9, 26.4). This study shows that E. coli 0157:H7 isolates yste- 
matically collected from a single geographic region over a defined time period exhibit 
considerable diversity in plasmid content and toxin genotype and that he toxin genotype 
of the infecting strain may influence the risk of developing microangiopathic sequelae. 
Enteric infection with Escherichia coli 0157:H7, a 
cytotoxin-producing organism first recognized as a 
human pathogen in 1982 [1], leads to a spectrum 
of illnesses that can include nonbloody diarrhea, 
hemorrhagic colitis, the hemolytic uremic syndrome 
(HUS), and thrombotic thrombocytopenic purpura 
(TTP) [2]. The incidence of HUS and TTP was re- 
ported to be low in two series of sporadic cases of 
cytotoxic E. coli infections [3, 4], but in outbreaks 
the proportion of patients developing these compli- 
cations has ranged from none [1] to 53^0 [5]. The 
reasons for this varying complication rate are un- 
clear. E. coli 0157:H7-related HUS and TTP are 
more common at the extremes of age [2], but even 
in reported outbreaks involving elderly patients the 
rates of HUS and TTP have ranged from 3^0 [6] to 
22^0 [7] of cases. Factors such as host response, in- 
oculum size, treatment, and possibly others may con- 
tribute to the highly variable rate of complications 
[2, 5], but strains of E. coli 0157:H7 may also vary 
in their ability to produce HUS and TTP. Although 
E. coli 0157:H7 isolates from multiple geographic 
areas and different time periods appear to be highly 
interrelated [8], they vary in plasmid content [9] and 
produce two antigenically distinct oxins known as 
Shiga-like toxins (SLT) I and II, also termed vero- 
toxins I and II [10]. 
To assess the relationship between strain variabil- 
ity characteristics and clinical illness, we performed 
plasmid analysis and genetic probing for SLT geno- 
type on patient isolates referred to the Washington 
State Public Health Laboratory as part of the first 
year of notifiable disease surveillance of E. coli 
0157:H7 infections [11]. Because clinical status was 
known, we could compare isolates from patients with 
and without HUS and TTP. 
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Methods 
During 1987, bacterial isolates referred to the 
Washington State Public Health Laboratory from 
93 different patients were confirmed as E. coli 0157: 
H7. All submitted isolates were plated on MacCon- 
key-sorbitol culture medium [12], and sorbitol-neg- 
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ative E. coli colonies were serotyped using tube ag- 
glutination for both the 0157 and H7 antigens. 
Isolates confirmed as E. coli 0157:H7 were stored 
at room temperature on brain-heart infusion agar 
slants. 
Clinical and epidemiologic data were collected in 
a standardized manner from case-patients (or their 
parents) with confirmed E. coli 0157:H7 infections 
and from their attending physician. Hemorrhagic co- 
litis was defined as acute grossly bloody or blood- 
streaked iarrhea (^3 loose or watery stools over a 
24-h period). Patients diagnosed with either HUS 
or TTP had the triad of acute microangiopathic ane- 
mia (hematocrit OOVo) with evidence of red cell 
fragmentation on a peripheral smear, a platelet count 
of ̂50,0007mm3 , and serum creatinine ^.0 mg/dl. 
Plasmids were analyzed by the method of Port- 
noy et al. [13], except hat isolates were grown in "L" 
broth instead of brain-heart infusion broth and there 
were minor modifications i  plasmid rying methods. 
SLTI and SLTII probes consisting of radiolabeled 
internal fragments of the respective toxin structural 
genes were used to determine SLT genotype [14]. 
Sample and control isolates grown on nutrient agar 
were transferred to Whatman 541 paper, steam dena- 
tured, neutralized, and dried as described in detail 
elsewhere [15]. Isolates were probed by P. I. T, who 
was blinded to the clinical data that accompanied 
the strains. 
Calculation of relative risks and confidence inter- 
vals was performed using the methods described by 
Thomas [16]. Stratified analysis, including the evalu- 
ation of interaction between variables, was done by 
the same methods. 
Results 
Eighty-eight (95^0) of the 93 isolates of E. coli 
0157:H7 were available for testing; the remaining 5 
had become nonviable during storage. The spectrum 
of illness represented bythese isolates included non- 
bloody diarrhea in 3 (3^0) patients, hemorrhagic co- 
litis (HC) in 74 (84^o), HC followed by HUS in 9 
(l(Wo), and HC followed by TTP in 2 (2*7o). The 5 
nonviable isolates were from patients with uncom- 
plicated HC. All isolates came from sporadic ases 
of illness, except for four pairs of isolates that came 
from members of the same household. In each of 
these pairs the isolates had similar plasmid profiles 
and toxin genotypes. 
Plasmid profiles. On plasmid analysis, a plas- 
mid of ~98 kilobase pairs (kbp) was present in all 
88 isolates (table 1). In 13 (ISVo) isolates, no other 
plasmids were detected, while the remaining 75 had 
1-4 additional plasmid bands. These bands ranged 
from 2 kbp to 87 kbp. A total of 13 plasmid pat- 
terns were observed, although four patterns ac- 
counted for 82^0 of the isolates. Table 1 lists the plas- 
mid profiles of isolates from patients by disease 
category. No individual plasmid or combination of 
plasmids was significantly associated with cases of 
HUS or TTP. 
Toxin genotype analysis. Each of the 88 E. coli 
0157:H7 isolates tested contained the gene sequence 
of at least one of the Shiga-like toxins. Of the iso- 
lates, 3 had only SLT I present, 18 (20^?) had only 
SLT II, and the rest (67, 76*70) had both SLT I and 
SLT II sequences. 
The age distribution fpatients by SLT genotype 
is shown in figure 1. While the mean and median 
ages of patients with isolates containing the three 
genotypes were similar, patients with only the SLT 
II sequence were more likely to be at the extremes 
of age. Fourteen (78^0) of 18 patients whose isolates 
had the SLT II sequence alone were ^0 y or ̂0 y 
old compared with 32 (46^0) of the 70 patients whose 
isolates had the other two genotypes (rate ratio [RR], 
1.7; 95^0 confidence interval [CI], 1.1, 2.2). 
Isolates of E. coli 0157:H7 containing solely the 
SLT II gene caused illness that progressed to HUS 
Table 1. Plasmid profiles of 88 Escherichia coli 0157:H7 
isolates from patients in the state of Washington, by clinical 
outcome, 1987. 
Plasmid Total 
profile (kbp) HUS-TTP Non-HUS-TTP (%) 
98,3 4 33 37 (42) 
98,6 1 14 15 (17) 
98 4 9 13 (15) 
98,60,3 1 6 7 (8) 
98,6,3 0 3 3 (3) 
98,33,6,2 0 3 3 (3) 
98,33,6 0 2 2 (2) 
98,60 1 1 2 (2) 
98,8,6,5 0 2 2 (2) 
98,33,3 0 1 1 (1) 
98,45 0 1 1 (1) 
98,87,3 0 1 1 (1) 
98,87,11,3 0 1 1 (1) 
Total 11 77 88(100) 
NOTE, kbp = kilobase pairs, HUS = hemolytic uremic syn- 
drome, TTP = thrombotic thrombocytopenic purpura. 
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B. SLT II only isolates 
Figure 1. Age distribution of pa- 
tients with Escherichia coli 0157:H7 
infections by (A) Shiga-like toxins 
(SLT) I and I and II and (B) SLT II 
only. HUS = hemolytic uremic syn- 





or TTP in 7 (39^0) of 18 patients. In contrast, only 
4 (6^0) of the 70 isolates with the other genotypes 
were from patients with these complications (RR, 
6.8; CI, 1.9, 26.4). When the analysis was restricted 
to patients at the age extremes indicated above 
(potentially the group at highest risk for HUS and 
TTP), a similar trend was seen; 43^0 (6/14) of the 
SLT II-only isolates were from HUS-TTP patients 
compared with 13^0 (4/32) of isolates with other 
genotypes (RR, 3.4; CI, 0.9, 12.8). 
Since age was associated with toxin genotype and 
toxin genotype was associated with systemic se- 
quelae, we examined the relationship between these 
two variables using the method of Thomas [16]. We 
controlled for one of these two variables while ex- 
amining the other with systemic sequelae being the 
outcome of interest for both. When controlling for 
toxin genotype, age was not a significant risk fac- 
tor for systemic sequelae (P = .08, two-tailed), but 
when controlling for age, a significant association 
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between toxin genotype and HUS and TTP was pres- 
ent (P = .01). 
Antimicrobial treatment history was known in 78 
of the 88 patients whose isolates were probed. Of 
the cases with known treatment status, 34 (44^0) re- 
ceived at least one antimicrobial while 44 (56^0) did 
not; 9 (53^0) of 17 patients infected with isolates con- 
taining only SLT II were treated compared with 25 
(41Vo) of 61 patients infected with the other geno- 
types. In both treated and untreated persons, those 
infected only with an SLT II organism had a higher 
risk of HUS and TTP. In the treated group, 4 (44Vo) 
of 9 SLT II-only isolates were from HUS-TTP pa- 
tients compared with 1 (4^0) of 25 isolates with the 
other genotypes (RR, 11.1; CI, 1.3,440.8). In the un- 
treated group, 3 (38^0) of 8 SLT II-only isolates were 
from HUS-TTP patients compared with 2 (6Vo) of 
36 isolates with the other genotypes (RR, 6.8; CI, 
0.9,58.9). Because the number of cases receiving in- 
dividual agents was small, the data were not ana- 
lyzed by individual antimicrobial agent. 
Discussion 
During the 12-mo study period, a significant associ- 
ation between toxin genotype and clinical outcome 
was found. E. coli 0157:H7 strains with the SLT II 
gene alone were more likely than the other genotypes 
to be isolated from patients with HUS or TTP. This 
finding was independent of age, which is an impor- 
tant risk factor for these complications, and an- 
timicrobial use. Similar trends have been noted else- 
where. As part of a study of E. coli 0157 isolates 
in Great Britain, Scotland et al. [17] noted that al- 
though most isolates in their series produced SLT 
II alone, these isolates were most common in cases 
of HUS. Tarr et al. [15], inastudy of E. coliO\5TMl 
isolates collected in the state of Washington during 
1984-1987 (including 16 patients reported here), also 
noted that organisms containing solely SLT II genes 
were more likely to cause a diarrheal syndrome 
progressing to HUS or TTP than were organisms 
with other genotypes (79^0 of genotypic SLT II or- 
ganisms were from HUS-TTP patients compared with 
47 Vo of organisms with the other genotypes). How- 
ever, in that series, the findings did not reach statisti- 
cal significance and the isolates were not collected 
systematically. 
We observed considerable strain variation among 
E. coli 0157:H7 clinical isolates drawn from a well- 
defined geographic area. At least 13 different plas- 
mid profiles and three Shiga-like toxin genotype 
combinations were detected. Our findings probably 
underestimate he actual strain variation in Washing- 
ton, since screening for E. coli 0157:H7 is not a stan- 
dard procedure in most clinical laboratories and the 
isolates referred were likely to be from more severely 
ill patients. Many laboratories creened for E. coli 
0157:H7 only if the stool specimen appeared bloody 
[11]; some investigators [3,4] have reported that non- 
bloody diarrhea in sporadic E. coli 0157:H7 infec- 
tion is unusual. Thus, if clinical manifestations are 
strain-related, failure to detect patients with mild or 
atypical illness might underestimate strain variation, 
but as E. coli 0157:H7 appears to be rare in cases 
of nonbloody diarrhea, it is unlikely that many cases 
were missed. 
It is unclear why E. coli 0157:H7 isolates with only 
the SLT II gene should be more likely to produce 
HUS and TTP. One possible explanation is that iso- 
lates with only the SLT II gene produce greater 
amounts of SLT II in vivo than do isolates with both 
toxin genes. Another possibility is that this SLT geno- 
type acts as a marker for other as yet unrecognized 
virulence characteristics. Evidence indicates that 
Shiga-like toxin plays a crucial role in the pathogen- 
esis of both the intestinal and extraintestinal man- 
ifestations of E. coli 0157:H7 infection [18], but 
other factors may also be important. Lastly, differ- 
ences in immunologic response to the infecting strain 
may play a role. Ashkenazi et al. [19] have demon- 
strated antibodies to SLT I, but not SLT II, in pooled 
commercial immunoglobulin. A brisk anamnestic 
response to strains producing SLT I may neutralize 
part or all of the systemic toxicity of the related, but 
distinct, SLT II. All of these hypotheses remain 
speculative until adequate animal models for hemor- 
rhagic colitis with subsequent systemic microan- 
giopathy are developed, allowing these hypotheses 
to be tested in a controlled fashion. 
The age-related ifferences noted between E. coli 
0157:H7 strains could result from these strains be- 
coming host- or food-adapted. If so, certain strains 
would preferentially infect certain segments of the 
population. An example would be a milk-specific 
strain associated with illness in children. Since food 
sources are difficult o implicate in sporadic cases, 
such relationships could not be assessed in our study. 
The absence of genotypic SLT II-only isolates in 
middle-aged patients is striking and may support the 
concept that strains are host adapted. No SLT II- 
only isolates were detected in patients between the 
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ages of 17 and 56 y, a group in which isolates with 
the SLT I gene were frequently found. 
Five isolates had become nonviable during stor- 
age. These isolates were from patients (four adults 
and one child) with HC and were not geographically 
or temporally related. Even in the unlikely event hat 
all of these isolates possessed only the SLT II gene, 
the relationship we found between this genotype and 
HUS-TTP would be little changed. Although stor- 
age could have altered plasmid profiles or toxin geno- 
type, several isolates were subjected to repeated plas- 
mid analysis over a 1-y period with no change in the 
profiles. Also, it is doubtful that strains from pa- 
tients with HUS or TTP would lose the SLT I gene 
more often than isolates from other patients. 
In summary, it appears that in Washington the 
relationship between E. coli 0157:H7 and the extrain- 
testinal manifestations of infection isin part deter- 
mined by characteristics of the infecting strain. It 
is likely that bacterial and host factors both play a 
role in determining the sequelae of hemorrhagic co- 
litis, since multiple clinical outcomes from a single 
strain oiE. coli 0157:H7 have been observed in the 
outbreak setting. However, our study shows that he 
genetic diversity of these organisms needs to be ad- 
dressed in assessing the spectrum of illness in per- 
sons with E. coli 0157:H7 infections. Further studies 
are needed to determine ifthis is also true in areas 
other than Washington. 
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